Effective Protection Against Acute Respiratory Distress Syndrome/sepsis Injury by Combined Adipose-derived Mesenchymal Stem Cells and Preactivated Disaggregated Platelets
Overview
Authors
Affiliations
This study assessed whether combining adipose-derived mesenchymal stem cells (ADMSC) with preactivated, disaggregated shape-changed platelets (PreD-SCP) was superior to either therapy alone for protecting rat lung from acute respiratory distress syndrome (ARDS) complicated by sepsis. ARDS and sepsis were induced through 100% oxygen inhalation and peritoneal administration of 1.5 mg/kg lipopolysaccharide (LPS), respectively. Adult-male Sprague-Dawley rats (n=40) were randomized into sham-control (SC), ARDS-LPS, ARDS-LPS-ADMSC (1.2x10 cells), ARDS-LPS-PreD-SCP (3.0x10, intravenous administration), and ARDS-LPS-ADMS/PreD-SCP groups, and were sacrificed 72 h after 48 h ARDS induction. Lung injury scores (LIS) and collagen deposition were highest in ARDS-LPS, lowest in SC, higher in ARDS-LPS+ADMSC than in ARDS-LPS+PreD-SCP and ARDS-LPS+ADMS/PreD-SCP, and higher in ARDS-LPS+PreD-SCP than in ARDS-LPS+ADMS/PreD-SCP (all p<0.0001). Alveolar-sac numbers, oxygen saturation, endothelial marker levels, and mitochondrial cytochrome-C levels exhibited opposite patterns with respect to LIS (all p<0.001). Levels of inflammatory, oxidative-stress, apoptosis, mitochondrial/DNA damage, and MAPK and Akt signaling markers exhibited patterns identical to that of LIS (all p<0.001). Anti-oxidant and anti-inflammatory protein levels increased progressively from SC to ARDS-LPS+ADMS/PreD-SCP (all p<0.0001). These findings indicate combined ADMSC/PreD-SCP was superior to either therapy alone for protecting rat lung from ARDS-sepsis injury.
Lin K, Fang W, Yeh J, Chiang J, Chiang H, Shao P World J Stem Cells. 2024; 16(6):690-707.
PMID: 38948095 PMC: 11212548. DOI: 10.4252/wjsc.v16.i6.690.
Sung P, Yin T, Chiang J, Chen C, Huang C, Lee M Stem Cells Transl Med. 2024; 13(8):724-737.
PMID: 38894649 PMC: 11328939. DOI: 10.1093/stcltm/szae034.
Lopes-Pacheco M, Rocco P Front Pharmacol. 2023; 14:1067422.
PMID: 37007034 PMC: 10062457. DOI: 10.3389/fphar.2023.1067422.
Nie S, Wang H, Liu Q, Tang Z, Tao W, Wang N BMC Pulm Med. 2022; 22(1):314.
PMID: 35971101 PMC: 9376578. DOI: 10.1186/s12890-022-02112-w.
Mesenchymal stem cells: a new front emerges in coronavirus disease 2019 treatment.
Raza S, Khan M Cytotherapy. 2022; 24(8):755-766.
PMID: 35880307 PMC: 7362822. DOI: 10.1016/j.jcyt.2020.07.002.